期刊
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
卷 17, 期 6, 页码 577-591出版社
TAYLOR & FRANCIS AS
DOI: 10.1080/14737159.2017.1326820
关键词
Ovarian cancer; biomarkers; CA125; HE4; monitoring; pelvic mass; early detection; cancer imaging
类别
资金
- Early Detection Research Network [5 U01 CA200462-02]
- MD Anderson Ovarian SPORE [P50 CA83639]
- National Cancer Institute, Department of Health and Human Services
- Cancer Prevention Research Institute of Texas [RP160145]
- National Institutes of Health [CA16672]
- Golfer's Against Cancer
- Mossy Foundation
- National Foundation for Cancer Research [88750]
- UT MD Anderson Women's Moon Shot
- UT MD Anderson Cancer Center Odyssey Program
- Theodore N. Law Endowment for Scientific Achievement
- Clyde H. Wright Memorial Fund
- Bristol-Myers Squibb Award in Clinical Research
Introduction: Despite advances in surgery and chemotherapy for ovarian cancer, 70% of women still succumb to the disease. Biomarkers have contributed to the management of ovarian cancer by monitoring response to treatment, detecting recurrence, distinguishing benign from malignant pelvic masses and attempting to detect disease at an earlier stage. Areas covered: This review focuses on recent advances in biomarkers and imaging for management of ovarian cancer with particular emphasis on early detection. Relevant literature has been reviewed and analyzed. Expert commentary: Rising or persistent CA125 blood levels provide a highly specific biomarker for epithelial ovarian cancer, but not an optimally sensitive biomarker. Addition of HE4, CA 72.4, anti-TP53 autoantibodies and other biomarkers can increase sensitivity for detecting early stage or recurrent disease. Detecting disease recurrence will become more important as more effective therapy is developed. Early detection will require the development not only of biomarker panels, but also of more sensitive and specific imaging strategies. Effective biomarker strategies are already available for distinguishing benign from malignant pelvic masses, but their use in identifying and referring patients with probable ovarian cancer to gynecologic oncologists for cytoreductive operations must be encouraged.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据